Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
11 juin 2019 09h00 HE
|
Denali Therapeutics Inc.
DNL310 on track to enter Phase 1/2 clinical study in Hunter Syndrome patients in 2020DNL310 utilizes Denali’s proprietary blood-brain barrier crossing enzyme transport vehicle (“ETV”) technologyTwo...
Denali Therapeutics Reports First Quarter 2019 Financial Results
08 mai 2019 16h30 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
12 mars 2019 09h00 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
15 févr. 2019 09h00 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
08 janv. 2019 09h00 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for...
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
10 déc. 2018 09h00 HE
|
Denali Therapeutics Inc.
Phase 1b study includes Parkinson’s disease patients with and without a genetic LRRK2 mutation SOUTH SAN FRANCISCO, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:...
Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
19 nov. 2018 16h30 HE
|
Denali Therapeutics Inc.
Phase 1 healthy volunteer study of DNL747 meets all endpoints, including CSF exposure levels, RIPK1 inhibition, and pathway engagement, at doses that were safe and well toleratedData from the Phase 1...
Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors
08 nov. 2018 16h30 HE
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative...
Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases
01 nov. 2018 02h00 HE
|
Denali Therapeutics Inc.
Candidate RIPK1 inhibitor molecules have the potential to treat Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseasesDenali to receive...
CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials
03 oct. 2018 09h00 HE
|
Denali Therapeutics Inc.
ROSTOCK, Germany and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global...